AI-generated from publicly available materials.Massive Bio has made its first investment in AI, supporting Rivvi, a startup focused on AI infrastructure for healthcare and life sciences. This partnership, revealed at the Ai4 conference in Las Vegas on August 4, 2026, aims to enhance patient engagement and clinical trial matching in oncology.
The collaboration seeks to bridge the gap in therapeutic clinical trial enrollment, which currently sees only 3% to 5% of U.S. adults with cancer participating. Factors such as fragmented data and complex eligibility criteria contribute to this challenge. Massive Bio will leverage its expertise in structuring clinical and biomarker data to identify relevant trials, while Rivvi will implement AI agents to streamline patient interactions and ensure follow-through on trial opportunities.
Massive Bio's established multi-agent matching system has shown promising results, achieving over 17,000 oncologist-confirmed matches and significantly improving the speed of trial matching compared to traditional methods. Rivvi, with its extensive experience in patient engagement, has facilitated over two million interactions, showcasing its capability to enhance communication between health systems and patients.
This investment represents a strategic pivot for Massive Bio, as it aims to integrate AI technologies that complement its existing offerings. By focusing on enhancing clinical intelligence and patient outreach, the partnership with Rivvi may redefine how patients are informed about and enrolled in clinical trials, ultimately improving outcomes in oncology.